First-Line Sequential Gemcitabine and Docetaxel Treatment for High-Risk Non-Muscle Invasive Bladder Cancer – Expert Commentary

bacillus Calmette-Guérin (BCG), transurethral resection of bladder tumor (TURBT), alternative intravesical therapies for high-risk NMIBC, high-risk non-muscle invasive bladder cancer (NMIBC).

Read the full article here

Related Articles